drugset / Trial / NCT06349473

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

NCT06349473 ↗

Phase 1 Recruiting 31 enrolled Equilibra Bioscience LLC
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).

Timeline

Start
2024-05-10
Primary completion
2026-09-28
Completion
2026-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject SR604 Unknown — Subcutaneous